PMID- 35118097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231102
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines.
PG  - 806641
LID - 10.3389/fmed.2021.806641 [doi]
LID - 806641
AB  - Over the past 2 years, the severe acute respiratory syndrome coronavirus 2 
      (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) and rapidly spread 
      worldwide. In the process of evolution, new mutations of SARS-CoV-2 began to 
      appear to be more adaptable to the diverse changes of various cellular 
      environments and hosts. Generally, the emerging SARS-CoV-2 variants are 
      characterized by high infectivity, augmented virulence, and fast 
      transmissibility, posing a serious threat to the prevention and control of the 
      global epidemic. At present, there is a paucity of effective measurements to cure 
      COVID-19. It is extremely crucial to develop vaccines against SARS-CoV-2 and 
      emerging variants to enhance individual immunity, but it is not yet known whether 
      they are approved by the authority. Therefore, we systematically reviewed the 
      main characteristics of the emerging various variants of SARS-CoV-2, including 
      their distribution, mutations, transmissibility, severity, and susceptibility to 
      immune responses, especially the Delta variant and the new emerging Omicron 
      variant. Furthermore, we overviewed the suitable crowd, the efficacy, and adverse 
      events (AEs) of current vaccines.
CI  - Copyright (c) 2022 Jiang, Wu, Song and You.
FAU - Jiang, Yao
AU  - Jiang Y
AD  - Laboratory Medicine Center, Lanzhou University Second Hospital, Lanzhou, China.
FAU - Wu, Qian
AU  - Wu Q
AD  - Laboratory Medicine Center, Lanzhou University Second Hospital, Lanzhou, China.
FAU - Song, Peipei
AU  - Song P
AD  - Laboratory Medicine Center, Lanzhou University Second Hospital, Lanzhou, China.
FAU - You, Chongge
AU  - You C
AD  - Laboratory Medicine Center, Lanzhou University Second Hospital, Lanzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220118
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8804231
OTO - NOTNLM
OT  - SARS-CoV-2
OT  - immune responses
OT  - mutations
OT  - transmissibility
OT  - vaccines
OT  - variants
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2022/01/18
CRDT- 2022/02/04 05:52
PHST- 2021/11/01 00:00 [received]
PHST- 2021/12/16 00:00 [accepted]
PHST- 2022/02/04 05:52 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2022/01/18 00:00 [pmc-release]
AID - 10.3389/fmed.2021.806641 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Jan 18;8:806641. doi: 10.3389/fmed.2021.806641. 
      eCollection 2021.